Approximately 40% of patients at intermediate stages of cancer, and 60 to 87% of patients with a generalized form of cancer, suffer from pain of varying intensity.

Morphine, and its derivatives, are strong analgesics and are widely used in clinical practice. However, their use is associated with serious side effects: physical and psychological dependence, tolerance, risk of respiratory depression, euphoria, CNS effects, etc. All these problems have long ago made the development of morphine alternatives based on new biochemical principles a matter of great importance.

Our peptide-based analgesic, delivers strong pain relief, is long lasting, and does not exhibit the usual opioid side effects. Taphalgin possesses a wide therapeutic range; and maintains stability when stored for long periods.

Taphalgin. Key Benefits

• High activity and duration of analgesic effects
• Wide therapeutic window and high safety, non-existent or weak side effects
• Does not accumulate in the body
• Does not induce euphoria
• No potential for drug abuse
• Unusable as a drug precursor
• Can be sold using conventional prescription methods

Taphalgin can be used in a wide range of applications

• Pain in adults with cancer
• Pain in children with cancer
• Myocardial infarction
• Postoperative period
• Analgesia during labor
• Injuries, burns
• Migraines and rheumatic pain
• Military first aid kits

Problem: No universal treatments for influenza and ARVI currently exist

• According to the WHO, there are about 300 ARVI pathogens of various etiologies.
• The emergence of new and recurring infections (influenza, coronavirus, bocavirus, meta-pneumovirus, rhinovirus infections, etc.), including a high rate of co-infections, and a decrease in the number of people who are immune to these infections, as well as an increase in the proportion of the population with atopic diseases, an enormous increase in migration, increase the susceptibility to respiratory infections, making timely diagnosis, treatment and prevention global and national healthcare priorities.
• There is still no universal antiviral agent that can protect against all respiratory pathogens responsible for influenza and ARVI.
• There is a high demand for preparations that do not act only on specific proteins and key structures of the virus, but also exert a multi-pronged effect on the cellular and humoral immune mechanisms of antiviral protection.
• Flu vaccines are not effective enough; vaccines against other acute respiratory viral infections do not exist.

Solution to the Problem: creation of a safe, effective broad-spectrum antiviral drug
Regardless of the pathogen, the upper respiratory tract, where the most intensive reproduction of viruses takes place in the epithelial cells, acts as the entry point for the infection.

The causative agents of ARVI are spread through airborne droplets, when coughing, sneezing, talking and through contaminated household items.

Arvidal– an antiviral immunotropic spray

A Drug based on one of the synthetic derivatives of an endogenous peptide of the enkephalin group, which has a wide range of regulatory capabilities; in particular, affecting the normalization of the biological functions of the human body.

The drug has both a direct antiviral effect and has a pronounced ability to stimulate factors of local and systemic immunological protection when administered as a spray through the nose and mouth.

It has both local and systemic effects for increasing the activity of the immune system, in particular, innate immunity, and, as a result, stimulating the protective mechanisms of adaptive immunity. It enhances the activity of the phagocytic immunity (macrophages and neutrophils), as well as the activity of natural killer cells. Stimulates the production of endogenous interferons.

It shows the ability to suppress excessive synthesis of pro-inflammatory cytokines (IL-1, IL-6, TNF-α), reduces the degree of intoxication and suppresses other manifestations of the inflammatory cascade.

It has a powerful effect for suppressing the action of pathogens of respiratory diseases. It has both a prophylactic effect when one is at risk of contracting a disease, and a pronounced therapeutic effect. When administered intra-nasally, it is characterized by antiviral and immunomodulatory effects comparable to intramuscular administration, which is especially important for clinical use.

Reduces the intensity of symptoms and pain during the development of the disease.

Application in the early stages of the development of the disease or preventively, prevents a person from getting sick. In the later stages of development of the disease, it enables the patient to experience a milder form of the disease, thereby accelerating the elimination of residual effects from colds.

Compatibility profile of the drug allows its use both as monotherapy, and in combination with other drugs.

Due to a sharp increase in the concentration of neutrophils and the activity of innate immunity in the focus of infection, the reproduction of pathogens is stopped in the early stages of the disease. ARVI severity is reduced by inhibiting the development of secondary complications in the form of bacterial acute respiratory infections during influenza. Another established property of the drug is the regenerative effect with local and systemic administration. This property allows to reduce damage to lung tissue during the development of severe forms of the disease.

Presented in a convenient dosage form - nasal spray. The patient sprays the 0.1 - 0.5% aqueous solution in the nasal cavity and inhaling, or by applying to the area of the throat and oral cavity through the mouth.

In pronounced cases of the disease with involvement of the upper respiratory tract and lungs, the aerosol could be administered on an outpatient basis by inhalation through an compressor or ultrasonic nebulizer.

Arvidal – Safe to use
Arvidal does not cause abnormalities of the cardiovascular system, no pathological changes in the ECG were detected. Not accompanied by changes in hematological, biochemical and hormonal parameters.

No local toxicity or local irritating action.
The drug belongs to toxicity class VI "Relatively safe substances".
No cumulative effects, addiction or dependence.

The Solution
Dalardenol. A peptide-based burn treatment and wound healing spray

Dalardenol is a burn treatment and wound healing agent that can be directly applied to the affected area, that acts on various mechanisms contributing to the healing of wounds of various aetiologies The principle of a unified topical and systemic therapy that underpins the treatment of patients with thermal burns. Special emphasis on topical treatment, which is aimed at the thorough healing of burn wounds and early restoration of the skin. Moreover, introduction of advanced treatment options such as reconstructive surgery and skin grafts or bio-membranes have increase demand.

Due to rising patient concerns regarding aesthetic appearance is a major factor attributed to the rising need for a drug such as Dalardenol. Furthermore, advantages in wound treatment, which are associated with the use of biologics, such as accelerated wound healing, are cost efficient, will result in a shorter hospital stay.

Functionality and Effectiveness

Dalardenol is a drug based on a synthetic derivative of an endogenous peptide of the enkephalin family, which has a wide range of regulatory effects on tissue regeneration in wound and burn areas. It provides pain relief, reduces inflammation, shields skin lesions from microorganisms, stimulates skin cell metabolism and ensures scare-free wound healing.

The application of Dalardenol is in the form an externally applied Spray and /or as a gel. The spray form allows large wound and burn surfaces to be quickly treated under virtually any conditions. The use of drug on the 1st day of injury, reduces the severity of redness of the skin. Moreover, Dalardenol is significantly superior to Dexpanthenol in reducing hyperaemia over time.

• Local application of Dalardenol immediately after a thermal injury reduces oedema and hyperaemia.
• The results obtained indicate the high efficiency of Dalardenol both as a first-aid treatment and for the subsequent therapy of moderate burns.
• The results suggest that Dalardenol can also be used for wound bed preparation in cases of deep burns, and to prepare for subsequent skin transplantation, and in the treatment of trophic ulcers in weakened patients with a low regenerative potential.